CAR-T FOR LYMPHOMA IN CHINA
— DLBCL, FOLLICULAR LYMPHOMA, AND BEYOND

China combines several factors that matter specifically for lymphoma CAR-T: multiple approved CD19 products including locally developed alternatives, lower pricing than equivalent products in the United States or Europe, mature ICU and supportive care infrastructure for cytokine release syndrome and neurotoxicity, and one of the most active trial portfolios globally for CD20, CD22, dual-target, and T-cell lymphoma CAR-T platforms. For patients facing limited options at home, particularly with double-refractory disease or rare subtypes, China often opens realistic pathways that would not otherwise exist.

Diffuse large B-cell lymphoma (DLBCL) DLBCL is the most common indication for CAR-T worldwide. Approved CD19 CAR-T products in China are used for relapsed or refractory disease after one or two prior lines, including primary refractory disease and early relapse. Outcomes are broadly comparable to international benchmarks at experienced centres, with durable complete remissions achievable in a meaningful proportion of patients. CAR-T is increasingly considered earlier in the treatment sequence rather than as a last resort, with second-line CAR-T now standard for high-risk relapsed DLBCL. High-grade B-cell lymphoma and double/triple-hit lymphoma High-grade B-cell lymphomas with MYC plus BCL2 or BCL6 rearrangements respond poorly to standard chemoimmunotherapy and represent a particularly important indication for CAR-T after frontline failure. Bridging therapy to control disease before CAR-T infusion is often essential, and structured planning between referring and treating teams matters significantly here. Primary mediastinal B-cell lymphoma (PMBCL) PMBCL responds to CD19 CAR-T similarly to DLBCL in relapsed or refractory disease. Younger patient demographics and the importance of avoiding long-term chemotherapy toxicity make CAR-T particularly relevant for this group. Follicular lymphoma Follicular lymphoma is generally indolent but becomes problematic with multiple relapses or transformation to aggressive lymphoma. CD19 CAR-T is now approved in some regions for relapsed follicular lymphoma after multiple prior lines, and Chinese centres offer both approved and trial-based access. Bispecific antibodies such as mosunetuzumab and epcoritamab are alternative options, with the choice depending on disease burden, prior therapy, and patient preference. Mantle cell lymphoma (MCL) Mantle cell lymphoma is a distinct B-cell malignancy with aggressive behaviour after BTK inhibitor failure. Brexucabtagene autoleucel and other CD19 CAR-T platforms have shown strong activity, and Chinese centres run both approved and trial pathways. Bridging therapy and careful management of high disease burden — particularly with lymphocytosis and rapid progression — are critical to a successful CAR-T outcome. Transformed lymphoma Indolent lymphomas (follicular, marginal zone, CLL/SLL) that transform into aggressive lymphoma represent a high-risk group where standard therapy is often insufficient. CD19 CAR-T is increasingly used here, and outcomes are improving as bridging strategies and patient selection mature. Central nervous system lymphoma Primary and secondary CNS lymphoma was historically excluded from CAR-T trials due to concern about neurotoxicity. Emerging data and trial protocols — particularly in China — now show that CAR-T can be delivered safely in selected CNS lymphoma cases with structured supportive care. This remains a specialist area requiring centres with specific experience. T-cell lymphomas T-cell lymphomas have historically lacked effective CAR-T options because targeting T-cell antigens risks affecting healthy T cells. China is one of the most active areas globally for T-cell lymphoma CAR-T, with trial platforms targeting CD7, CD30, CD5, and TRBC1. For peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, and ALK-negative anaplastic large cell lymphoma after standard therapy, Chinese trial-based CAR-T is one of the few realistic pathways. Hodgkin lymphoma CD30-targeted CAR-T is being actively developed for relapsed Hodgkin lymphoma after brentuximab vedotin and checkpoint inhibitor failure. Chinese centres run several CD30 CAR-T trials, often combined with checkpoint inhibitors. This is trial-based access, with eligibility depending on prior therapy and disease characteristics.

CAR-T eligibility depends on confirmed histology, antigen expression by immunohistochemistry or flow cytometry, prior therapy lines, response to bridging therapy, organ function (cardiac, pulmonary, renal, hepatic), absence of active uncontrolled infection, and overall fitness. Bridging therapy — chemotherapy, radiation, BTK inhibitors, or bispecifics depending on subtype — is often essential to control disease between leukapheresis and infusion. Patients with very high disease burden or rapid progression have lower CAR-T success rates and need careful pre-treatment optimisation.

Case review — diagnosis, subtype, antigen expression, and prior treatment are reviewed to assess whether CAR-T in China is realistic and which platform fits best. Hospital and trial matching — reports are shared with appropriate Chinese CAR-T centres and trial teams for structured feedback before any travel. Treatment planning — approved CD19 products, trial-based CD20, CD22, dual-target, and T-cell lymphoma platforms, plus bridging strategies are mapped against the patient's case. Logistics — patients receive guidance on realistic cost ranges, expected stay duration of four to six weeks, visa, accommodation, interpreter support, and follow-up planning. Continuity of care — communication with hospital teams, monitoring schedules, and post-CAR-T care including infection management and immunoglobulin support after returning home are coordinated through a single point of contact.

Comprehensive lymphoma CAR-T care in China is concentrated in major haematology centres in Beijing, Shanghai, Tianjin, Guangzhou, Suzhou, and other cities, with several hospitals running high-volume CAR-T programmes treating hundreds of patients annually. The same disease may have different eligibility rules, cost structures, admission timelines, and trial access depending on the centre. CancerFax helps patients identify the most relevant pathway based on case volume, subtype expertise, trial portfolio, and international patient experience — not by hospital name alone.

Frequently Asked Questions

Answers to common questions from patients and families.